美股异动 | Eikon Therapeutics(EIKN.US)登陆纳斯达克开盘跌超5%_老虎社区_美港股上老虎

美股异动 | Eikon Therapeutics(EIKN.US)登陆纳斯达克开盘跌超5%

智通财经02-06

智通财经APP获悉，周四，Eikon Therapeutics(EIKN.US)登陆纳斯达克，开盘跌超5%，报17.05美元，IPO价格为18美元。Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年创立，公司目前正布局多款癌症实验性疗法研发管线。公司研发进度最快的候选药物EIK1001，正与默沙东(MRK.US)的Keytruda联合开展一款皮肤癌的中后期临床试验，该研究的中期分析数据预计将于2026年下半年公布。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2609258870?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-06 00:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609258870","market":"sh","top_or_hot":-1,"title":"美股异动 | Eikon Therapeutics(EIKN.US)登陆纳斯达克 开盘跌超5%","media":"智通财经","content":"<html><body><p>智通财经APP获悉，周四，<a href=\"https://laohu8.com/S/EIKN\">Eikon Therapeutics</a>(EIKN.US)登陆纳斯达克，开盘跌超5%，报17.05美元，IPO价格为18美元。Eikon <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年创立，公司目前正布局多款癌症实验性疗法研发管线。公司研发进度最快的候选药物EIK1001，正与<a href=\"https://laohu8.com/S/MRK\">默沙东</a>(MRK.US)的Keytruda联合开展一款皮肤癌的中后期临床试验，该研究的中期分析数据预计将于2026年下半年公布。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | Eikon Therapeutics(EIKN.US)登陆纳斯达克 开盘跌超5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | Eikon Therapeutics(EIKN.US)登陆纳斯达克 开盘跌超5%\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2026-02-06 00:13</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，周四，<a href=\"https://laohu8.com/S/EIKN\">Eikon Therapeutics</a>(EIKN.US)登陆纳斯达克，开盘跌超5%，报17.05美元，IPO价格为18美元。Eikon <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年创立，公司目前正布局多款癌症实验性疗法研发管线。公司研发进度最快的候选药物EIK1001，正与<a href=\"https://laohu8.com/S/MRK\">默沙东</a>(MRK.US)的Keytruda联合开展一款皮肤癌的中后期临床试验，该研究的中期分析数据预计将于2026年下半年公布。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1402306.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1402306.html","article_id":"2609258870","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609258870","pubTimestamp":1770308025,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，周四，Eikon Therapeutics(EIKN.US)登陆纳斯达克，开盘跌超5%，报17.05美元，IPO价格为18美元。Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年创立，公司目前正布局多款癌症实验性疗法研发管线。公司研发进度最快的候选药物EIK1001，正与默沙东(MRK.US)的Keytruda联合开展一款皮肤癌的中后期临床试验，该研究的中期分析数据预计将于2026年下半年公布。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK4550":"红杉资本持仓","UWM":"罗素2000指数ETF两倍做多","BK4007":"制药","RWM":"罗素2000指数反向ETF","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","TZA":"罗素2000指数三倍做空ETF","BK4539":"次新股","QYLD":"纳斯达克100 Covered Call ETF-Global X","SRTY":"罗素2000指数三倍做空ETF-ProShares","BK4581":"高盛持仓","SQQQ":"纳指三倍做空ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares","QYLG":"Nasdaq 100 Covered Call & Growth ETF","IWO":"罗素2000成长股指数ETF","TWM":"罗素2000指数两倍做空ETF","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","BK1147":"投资银行业与经纪业","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","USAW.SI":"AMZN 3xLongSG261006","BK4139":"生物科技","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","NVIW.SI":"NVDA 3xLongSG261006","BK4535":"淡马锡持仓","QID":"两倍做空纳斯达克指数ETF-ProShares","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","TQQQ":"纳指三倍做多ETF","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","TSYW.SI":"TESLA 3xLongSG261006","IWN":"罗素2000价值股指数ETF-iShares","TNA":"罗素2000指数三倍做多ETF-Direxion","USJW.SI":"ALPHAB 3xLongSG261006","PSQ":"做空纳斯达克100指数ETF-ProShares","EIKN":"Eikon Therapeutics"},"translate_title":"U.S. stock changes | Eikon Therapeutics (EIKN.US) landed on Nasdaq and opened down more than 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWM":0.6,"QYLD":0.6,"TNA":0.6,"TSYW.SI":0.6,"EIKN":1.98,"TZA":0.6,"UWM":0.6,"IWN":0.6,"GPIQ":0.6,"QLD":0.6,"IWO":0.6,"TQQQ":0.6,"PSQ":0.6,"QQQJ":0.6,"QYLG":0.6,"SRTY":0.6,"SQQQ":0.6,"RWM":0.6,"USAW.SI":0.6,"NVIW.SI":0.6,"JEPQ":0.6,"QQQE":0.6,"QQQY":0.6,"QID":0.6,"USJW.SI":0.6,"MNQmain":0.6},"content_text":"智通财经APP获悉，周四，Eikon Therapeutics(EIKN.US)登陆纳斯达克，开盘跌超5%，报17.05美元，IPO价格为18美元。Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年创立，公司目前正布局多款癌症实验性疗法研发管线。公司研发进度最快的候选药物EIK1001，正与默沙东(MRK.US)的Keytruda联合开展一款皮肤癌的中后期临床试验，该研究的中期分析数据预计将于2026年下半年公布。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}